Glaucoma Research Foundation receives $1.6 million gift

Article

The Glaucoma Research Foundation has received the largest single gift in its 32 year history. The staggering $1.6 million gift from the Melza M. and Frank Theodore Barr Foundation and is to support the ongoing research of the Catalyst For a Cure consortium to discover a cure for glaucoma.

The Glaucoma Research Foundation has received the largest single gift in its 32 year history. The staggering $1.6 million gift from the Melza M. and Frank Theodore Barr Foundation and is to support the ongoing research of the Catalyst For a Cure consortium to discover a cure for glaucoma. “The Barrs have been very generous in their support of glaucoma research and their gift will have a major impact on the effort to find new treatments and eventually a cure for glaucoma,” said Thomas Brunner, president and CEO of Glaucoma Research Foundation.

The Catalyst For a Cure research consortium is in its ninth year and takes a unique approach to glaucoma research. Unlike conventional research, which often operates in isolation until results can be published, the Catalyst For a Cure was formed with the goal of real time collaboration to speed the process of discovery. Four principal scientists at four universities brought their experience in neuroscience, genetics, molecular biology and vision to curing glaucoma, the second leading cause of blindness worldwide. Together the team has accelerated the pace of discovery and brought new understanding to vision loss from glaucoma. The principal scientists include Monica Vetter, PhD, University of Utah, Nick Marsh-Armstrong, PhD, Johns Hopkins University, Phil Horner, PhD, University of Washington, and David Calkins, PhD, Vanderbilt University.

Read more about the work of CFC.

www.glaucoma.org

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.